Abstract
Cannabinoids are found to be very useful in psychiatry because of their antipsychotic properties suggesting a therapeutic use as neuroleptic agents in limiting psychotic diseases. Cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation. In the present review, we reported recent studies supporting the idea that the cannabinoid system may modulate the activity of the striatum and temporal cortex linked to psychosis and schizophrenia. Furthermore, anatomical, electrophysiological, pharmacological and biochemical data suggest that the psychotic disorders related to the impaired cannabinoid system may lead to the development of novel compounds that selectively target specific elements of the cannabinoid system.
Keywords: Antipsychotics, Cannabis sativa, Cannabinoids, Cannabidiol, THC, Natural products, Schizophrenia.
Current Topics in Medicinal Chemistry
Title:Cannabinoids for the Treatment of Schizophrenia: An Overview
Volume: 16 Issue: 17
Author(s): Anna Capasso, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi and Luca Rastrelli
Affiliation:
Keywords: Antipsychotics, Cannabis sativa, Cannabinoids, Cannabidiol, THC, Natural products, Schizophrenia.
Abstract: Cannabinoids are found to be very useful in psychiatry because of their antipsychotic properties suggesting a therapeutic use as neuroleptic agents in limiting psychotic diseases. Cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation. In the present review, we reported recent studies supporting the idea that the cannabinoid system may modulate the activity of the striatum and temporal cortex linked to psychosis and schizophrenia. Furthermore, anatomical, electrophysiological, pharmacological and biochemical data suggest that the psychotic disorders related to the impaired cannabinoid system may lead to the development of novel compounds that selectively target specific elements of the cannabinoid system.
Export Options
About this article
Cite this article as:
Capasso Anna, Sobarzo-Sánchez Eduardo, Fazel Nabavi Seyed and Rastrelli Luca, Cannabinoids for the Treatment of Schizophrenia: An Overview, Current Topics in Medicinal Chemistry 2016; 16 (17) . https://dx.doi.org/10.2174/1568026616666160204122033
DOI https://dx.doi.org/10.2174/1568026616666160204122033 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Ligands at 5-HT and DA Receptors for the Treatment of Neuropsychiatric Disorders (Guest Editor: Giuseppe Di Giovanni) ]
Current Topics in Medicinal Chemistry Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Takotsubo Cardiomyopathy
Current Pharmaceutical Design Recent Advances on Horizontal Lower Limb Rehabilitation Robot
Recent Patents on Mechanical Engineering Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations
Recent Patents on Biomedical Engineering (Discontinued) Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Motor Complications in Parkinson’s Disease: A Comprehensive Review of Emergent Management Strategies
CNS & Neurological Disorders - Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 10
Current Pharmaceutical Design The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology PET Imaging in Parkinsons Disease
Current Medical Imaging Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy The Role of Phase Image in the Detection of Myocardial Dyskinesia by Magnetic Resonance Imaging (MRI)
Current Medical Imaging Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism